Page 31 - Sun Pharma

India biz may stabilise in FY19, but govt price caps a concern: Sun Pharma

The company's India business revenues stood at Rs 80.29 billion in 2017-18, a growth of 4 per cent over 2016-17

Sun Pharma looks to grow complex generics, specialty products biz faster

This strategy will entail taking multiple initiatives, both organic and inorganic as well as assuming measured risks

Sun Pharma gets Australian health regulator's nod for plaque psoriasis drug

ILUMYA is one of the key specialty products of Sun Pharma and it was approved by the US health regulator USFDA in March 2018 while the European Commission approved it in September 2018

First USFDA approval for Sun Pharma's Halol plant after warnings

This speciality drug, Sun claimed, is the first and only form of latanoprost that is not formulated with benzalkonium chloride

Sun Pharma shares gain 4% after declining 7% in past three days

The stock has moved higher by 4% to Rs 655, bouncing back 6% from its early morning low of Rs 620 on the BSE on Wednesday.

Sun Pharma's Halol plant is in trouble yet again, gets USFDA observations

Halol, a key plant for the drug maker to manufacture injectables and specialty drugs, was under regulatory scanner since 2014

Sun Pharma gets 6 observations by US FDA after inspection at Halol facility

Shares of Sun Pharmaceutical Industries on Friday closed at Rs 664.20 per scrip on BSE, down 1.84 per cent from its close

Sun Pharma erases losses post clarification on USFDA observations

The stock hit an intra-day high of Rs 670, recovering 4.7% from its early morning low of Rs 640 on the NSE.

Sun Pharma falls 5% on reports of USFDA issues observations

In past three months, Sun Pharma had outperformed the market by surging 38% as compared to a 9% rise in the benchmark index till Thursday.

Sun Pharma, Glenmark Pharma, Hikal hit 52-week highs; Aurobindo surges 8%

Granules India, Hikal, Pfizer, Lincoln Pharmaceuticals, Astrazeneca Pharma India and Aarti Drugs were up between 4% and 7%.

Improved US prospects, domestic outlook to drive Sun Pharma's earnings

The key near-term trigger is the company's specialty pipeline

Pharma shares extend rally; Dr Reddy's, Sun Pharma hit 52-week high

In past 14 trading days, Nifty Pharma index outperformed the market by surging 15% as compared to 2.3% rise in Nifty 50 index.

Nifty Pharma index set to post sharpest monthly rally in 9 years

Nifty Pharma index hit a fresh 52-week high of 10,390 in intra-day on Friday, rallying 13% thus far in the month of August, its sharpest monthly gain since September 2009.

US drug regulator inspects Sun Pharmaceutical's Halol plant in Gujarat

Sun Pharma had recalled around 5,000 units of 10 ml vials of testosterone cypionate injections from the US

Nifty Pharma index hits over six-month high; Sun Pharma at 14-month high

Thus far in current week, the Nifty Pharma index outperformed the market by surging 7% against a marginal 0.31% rise in the Nifty 50 index.

Sun Pharma hits 52-week high on USFDA approval, good Q1 results

Sun Pharm hit a 52-week high of Rs 618, up 3%, extending its Tuesday's 7% rally on the BSE.

Earnings upgrades ahead for Sun Pharmaceutical, stock gains nearly 7%

US growth at 8%, despite declining Taro sales, giving confidence that the firm is on a recovery path in America

Sun Pharma posts Rs 9.8 bn Q1 profit, beats estimates as US sales climb

Sales from its US formulations business, which constitutes over a third of total sales, grew 8 per cent from the previous corresponding quarter

Sun Pharma rallies 7% as Q1 profit beats Street estimates

The stock rallied 7% to Rs 600 on the BSE after the company reported a better-than-expected consolidated net profit at Rs 9.83 billion in June quarter.

Pharma shares in focus; Nifty Pharma index hits 6-month high

Divi's Lab, Aurobindo Pharma, Lupin, Dr Reddy's Lab, Sun Pharma, Glenmark Pharma and Cipla from the Nifty pharma index were up in the range of 1% to 3% on the NSE.